Genito-urinary Cancer

P1, N=15, Recruiting, South Metropolitan Health Service | Not yet recruiting --> Recruiting

P=N/A, N=1950, Recruiting, Australian and New Zealand Urogenital and Prostate Cancer Trials Group | Not yet recruiting --> Recruiting

P3, N=280, Active, not recruiting, University Medical Center Groningen | Recruiting --> Active, not recruiting | Trial completion date: Dec 2024 --> Dec 2027 | Trial primary completion date: Dec 2024 --> Oct 2027

P=N/A, N=4500, Enrolling by invitation, Fondazione del Piemonte per l'Oncologia | Not yet recruiting --> Enrolling by invitation | Trial primary completion date: Jan 2026 --> Jun 2026

P=N/A, N=235, Recruiting, University Hospital, Ghent | Trial primary completion date: Dec 2025 --> Jan 2027

P=N/A, N=194, Recruiting, Columbia University | Trial primary completion date: Dec 2024 --> Dec 2025

P3, N=200, Recruiting, Institute of Cancer Research, United Kingdom | Trial primary completion date: May 2025 --> May 2027

P1/2, N=45, Not yet recruiting, Milton S. Hershey Medical Center | Trial completion date: Jan 2028 --> May 2028 | Trial primary completion date: Jan 2027 --> May 2027

Transcriptome sequencing revealed that the expression of apoptosis-related genes (Capn1, Capn2, Bax, Aifm1, Caspase 3, Map3k5, Itpr1 and Fas) was down-regulated in spermatocytes of cryptorchid Trpv1-/- mice. Our results suggest that TRPV1 promotes the apoptosis of spermatocytes in cryptorchid mice by regulating the expression of apoptosis-related genes.

The demonstrated delays in definitive deterioration in GHS/QoL, urinary symptoms, and other functioning and symptom scales with talazoparib plus enzalutamide compared with placebo plus enzalutamide in patients with HRR-deficient metastatic castration-resistant prostate cancer provide insight that might inform clinical decisions for these patients.

Talazoparib plus enzalutamide prolonged time to definitive deterioration in GHS/QoL versus placebo plus enzalutamide. Together with clinical efficacy and safety data, these results inform the risk-benefit assessment of talazoparib plus enzalutamide in patients with metastatic castration-resistant prostate cancer in TALAPRO-2.

By integrating clinical insights with molecular data, this paper sheds light on the mechanisms driving oncocytic transformation and underscores the role of pathologists in identifying hereditary cancer syndromes.

Overexpression of P2RX4 occurred in multi cancers, and was connected to an unfavorable prognosis. This pan-cancer analysis highlighted the predictive value and tumorigenic role of P2RX4.

P=N/A, N=146, Active, not recruiting, Stanford University | Trial completion date: Dec 2026 --> May 2026

P2, N=27, Active, not recruiting, H. Lee Moffitt Cancer Center and Research Institute | Trial completion date: Mar 2025 --> Oct 2025

P=N/A, N=74, Recruiting, University of Lausanne Hospitals | Not yet recruiting --> Recruiting | Initiation date: Aug 2024 --> Nov 2024

P2/3, N=700, Recruiting, Vasgene Therapeutics, Inc | Not yet recruiting --> Recruiting | Initiation date: Nov 2024 --> Mar 2025

P=N/A, N=213, Completed, Oslo University Hospital | Recruiting --> Completed

P=N/A, N=60, Recruiting, The First Affiliated Hospital with Nanjing Medical University

P=N/A, N=21081, Active, not recruiting, Memorial Sloan Kettering Cancer Center | Trial completion date: Mar 2025 --> Mar 2026 | Trial primary completion date: Mar 2025 --> Mar 2026

P=N/A, N=550, Recruiting, Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University

The FRGs model offers a novel approach for prognostic prediction of ccRCC patients and has the potential to provide personalized prognostic prediction and treatment for ccRCC patients.

The restoration of c-Myc or ACLY expression attenuated the inhibitory effects of RNF112 on BLCA cell growth, migration, and lipid synthesis. In conclusion, this study confirmed that RNF112 suppressed the proliferation, migration, and lipid synthesis of BLCA cells by facilitating the ubiquitin-mediated degradation of c-Myc.

Indeed, ccRCC lines lacking all three pRB family members remained at least partially HIF2a-dependent. In this context, however, a kinase-defective Cyclin D1 variant partially overrode belzutifan's antiproliferative effects, suggesting that ccRCC promotion by Cyclin D1 requires the phosphorylation of pRB paralogs and one or more kinase-independent Cyclin D1 activities.

The study supports the potential of METTL3 as a prognostic biomarker in CRC and highlights its involvement in immune modulation and cancer progression. These findings lay the groundwork for future studies aimed at developing targeted therapies and improving patient outcomes.

Identifying potential therapeutic targets within the TME can improve outcomes for MIBC patients. This review emphasizes the TME's complexity and its impact on guiding novel therapeutic approaches, offering hope for better survival in MIBC.

Incorporating PCA3 and T:E into PCPTRC2 substantially enhances diagnostic accuracy for detecting PCa in biopsy-naïve patients. Despite limitations, these findings underscore the potential for optimizing risk calculators in clinical practice, advocating for larger cohorts to validate these results.

P1/2, N=68, Recruiting, Memorial Sloan Kettering Cancer Center | Trial completion date: Nov 2025 --> Nov 2026 | Trial primary completion date: Nov 2025 --> Nov 2026

P4, N=20, Not yet recruiting, Hamilton Health Sciences Corporation

These results indicate useful properties of red deer antler stem cell culture medium that can control molecular and cellular mechanisms that halt carcinogenesis. All these can be considered targets for further cancer stem cell treatment or cancer diagnostic improvements.

Notably, several diterpenoid alkaloids were more potent against MDR subline KB-VIN cells than the parental drug-sensitive KB cells. Among non-cytotoxic synthetic analogues, several lycoctonine-type C19-diterpenoid alkaloid derivatives effectively and significantly sensitized MDR cells to three anticancer drugs, paclitaxel, vincristine, and doxorubicin.

By detailing the distinctive morphology, immunophenotype, and molecular traits of this ESC RCC case, we have outlined the histological, immunohistochemical, and molecular features of this new renal tumor type, and reviewed relevant literatures for a comprehensive understanding. Our findings expand current knowledge of ESC RCC and can assist in reducing misdiagnosis.

This study reveals that GAMT has pro-oncogenic abilities in promoting ccRCC development and progression. GAMT exerted its non-enzymatic functions possibly by regulating the expression of p53. Fisetin, the novel GAMT inhibitor identified herein, may serve as a new antitumor drug for ccRCC treatment.

P2, N=30, Active, not recruiting, CatalYm GmbH | Recruiting --> Active, not recruiting | Trial completion date: Apr 2026 --> Sep 2026 | Trial primary completion date: Apr 2025 --> Aug 2025

Three weeks of voluntary wheel running was effective in delaying tumor formation and progression, which coincided with reduced transcription of DNA replication, AR signaling targets and mitochondrial dynamics. We further identified a downregulation in molecular pathways related to angiogenesis that may be responsible for the delayed tumor formation and progression by voluntary wheel running.

Occludin staining was unrelated to parameters of tumor aggressiveness in breast, gastric, endometrial, and thyroidal cancer. Our data demonstrate significant levels of occludin expression in many different tumor entities and identify reduced occludin expression as a potentially useful prognostic feature in several tumor entities.

P2, N=99, Active, not recruiting, Boehringer Ingelheim | Trial completion date: Jun 2025 --> Oct 2025

P1, N=1274, Active, not recruiting, Exelixis | Recruiting --> Active, not recruiting | Trial completion date: May 2026 --> Jun 2030 | Trial primary completion date: Feb 2026 --> Jun 2030

P1/2, N=240, Recruiting, A2 Biotherapeutics Inc. | Not yet recruiting --> Recruiting

P=N/A, N=30, Not yet recruiting, Chinese PLA General Hospital; Chinese PLA General Hospital

P=N/A, N=70, Recruiting, Peking University Shenzhen Hospital; Peking University Shenzhen Hospital

P=N/A, N=0, Not yet recruiting, Sun Yat-sen Memorial Hospital; Sun Yat-sen Memorial Hospital